Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance

Molecular Therapy

Volumn 23, Issue 4, 2015, Pages 627-637

  Hayashita Kinoh, Hiromi ^a   Yugeta, Naoko ^a   Okada, Hironori ^a   Nitahara Kasahara, Yuko ^a   Chiyo, Tomoko ^a   Okada, Takashi ^a   Takeda, Shin'Ichi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENE THERAPY AGENT; LUCIFERASE; MICRODYSTROPHIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; DYSTROPHIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG EFFICACY; FEMALE; FETUS; GAIT; GENE DOSAGE; GENE EXPRESSION; HEART FUNCTION; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFANT; INTRA-AMNIOTIC DRUG ADMINISTRATION; MALE; MUSCULAR DYSTROPHY; NONHUMAN; PHENOTYPE; RESPIRATORY FUNCTION; T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; X LINKED MUSCULAR DYSTROPHY; AMNION; ANIMAL; DEPENDOPARVOVIRUS; DOG DISEASES; GENE THERAPY; GENE TRANSFER; GENETICS; IMMUNOLOGY; LUNG FUNCTION TEST; MUSCULAR DYSTROPHY, ANIMAL; X CHROMOSOME LINKED DISORDER;

CANIS FAMILIARIS;

AMNION; ANIMALS; DEPENDOVIRUS; DOG DISEASES; DOGS; DYSTROPHIN; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC DISEASES, X-LINKED; GENETIC THERAPY; IMMUNE TOLERANCE; MALE; MUSCULAR DYSTROPHY, ANIMAL; PHENOTYPE; RESPIRATORY FUNCTION TESTS;

EID: 84927055827     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.5     Document Type: Article

References (55)

1. Yoshimura, M, Sakamoto, M, Ikemoto, M, Mochizuki, Y, Yuasa, K, Miyagoe-Suzuki, Y et al. (2004). AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 10: 821-828.
2. Yuasa, K, Sakamoto, M, Miyagoe-Suzuki, Y, Tanouchi, A, Yamamoto, H, Li, J et al. (2002). Adeno-associated virus vector-mediated gene transfer into dystrophindeficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther 9: 1576-1588.
3. Shin, JH, Nitahara-Kasahara, Y, Hayashita-Kinoh, H, Ohshima-Hosoyama, S, Kinoshita, K, Chiyo, T et al. (2011). Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. Gene Ther 18: 910-919.
4. Gregorevic, P, Blankinship, MJ, Allen, JM and Chamberlain, JS (2008). Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther 16: 657-664.
5. Yokota, T, Lu, QL, Partridge, T, Kobayashi, M, Nakamura, A, Takeda, S et al. (2009). Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65: 667-676.
6. Yugeta, N, Urasawa, N, Fujii, Y, Yoshimura, M, Yuasa, K, Wada, MR et al. (2006). Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovasc Disord 6: 47.
7. Koo, T, Okada, T, Athanasopoulos, T, Foster, H, Takeda, S and Dickson, G (2011). Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J Gene Med 13: 497-506.
8. Kornegay, JN, Li, J, Bogan, JR, Bogan, DJ, Chen, C, Zheng, H et al. (2010). Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 18: 1501-1508.
9. Pichavant, C, Chapdelaine, P, Cerri, DG, Dominique, JC, Quenneville, SP, Skuk, D et al. (2010). Expression of dog microdystrophin in mouse and dog muscles by gene therapy. Mol Ther 18: 1002-1009.
10. Shin, JH, Yue, Y, Srivastava, A, Smith, B, Lai, Y and Duan, D (2012). A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther 23: 202-209.
11. Wang, Z, Storb, R, Halbert, CL, Banks, GB, Butts, TM, Finn, EE et al. (2012). Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther 20: 1501-1507.
12. Sampaolesi, M, Blot, S, D'Antona, G, Granger, N, Tonlorenzi, R, Innocenzi, A et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444: 574-579.
13. Ohshima, S, Shin, JH, Yuasa, K, Nishiyama, A, Kira, J, Okada, T et al. (2009). Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 17: 73-80.
14. Yuasa, K, Yoshimura, M, Urasawa, N, Ohshima, S, Howell, JM, Nakamura, A et al. (2007). Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 14: 1249-1260.
15. Zhu, J, Huang, X and Yang, Y (2009). The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 119: 2388-2398.
16. Mendell, JR, Campbell, K, Rodino-Klapac, L, Sahenk, Z, Shilling, C, Lewis, S et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363: 1429-1437.
17. Wang, Z, Kuhr, CS, Allen, JM, Blankinship, M, Gregorevic, P, Chamberlain, JS et al. (2007). Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15: 1160-1166.
18. Sabatino, DE, Mackenzie, TC, Peranteau, W, Edmonson, S, Campagnoli, C, Liu, YL et al. (2007). Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice. Mol Ther 15: 1677-1685.
19. Waddington, SN, Buckley, SM, Nivsarkar, M, Jezzard, S, Schneider, H, Dahse, T et al. (2003). In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood 101: 1359-1366.
20. Waddington, SN, Nivsarkar, MS, Mistry, AR, Buckley, SM, Kemball-Cook, G, Mosley, KL et al. (2004). Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood 104: 2714-2721.
21. Day, MJ (2007). Immune system development in the dog and cat. J Comp Pathol 137 Suppl 1: S10-S15.
22. Shimatsu, Y, Yoshimura, M, Yuasa, K, Urasawa, N, Tomohiro, M, Nakura, M et al. (2005). Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 24: 145-154.
23. Yang, EY, Flake, AW and Adzick, NS (1999). Prospects for fetal gene therapy. Semin Perinatol 23: 524-534.
24. Koppanati, BM, Li, J, Reay, DP, Wang, B, Daood, M, Zheng, H et al. (2010). Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene. Gene Ther 17: 1355-1362.
25. David, A, Cook, T, Waddington, S, Peebles, D, Nivsarkar, M, Knapton, H et al. (2003). Ultrasound-guided percutaneous delivery of adenoviral vectors encoding the betagalactosidase and human factor IX genes to early gestation fetal sheep in utero. Hum Gene Ther 14: 353-364.
26. Malmquist, W (1968). Bovine viral diarrhea-mucosal disease: etiology, pathogenesis and applied immunity. J Am Vet Med Assoc 152: 763-768.
27. McClurkin, AW, Littledike, ET, Cutlip, RC, Frank, GH, Coria, MF and Bolin, SR (1984). Production of cattle immunotolerant to bovine viral diarrhea virus. Can J Comp Med 48: 156-161.
28. Zhang, P, Sun, B, Osada, T, Rodriguiz, R, Yang, XY, Luo, X et al. (2012). Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther 23: 460-472.
29. Brace, RA (1995). Progress toward understanding the regulation of amniotic fluid volume: water and solute fluxes in and through the fetal membranes. Placenta 16: 1-18.
30. Douar, AM, Adebakin, S, Themis, M, Pavirani, A, Cook, T and Coutelle, C (1997). Foetal gene delivery in mice by intra-amniotic administration of retroviral producer cells and adenovirus. Gene Ther 4: 883-890.
31. Mitchell, M, Jerebtsova, M, Batshaw, ML, Newman, K and Ye, X (2000). Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Ther 7: 1986-1992.
32. Sekhon, HS and Larson, JE (1995). In utero gene transfer into the pulmonary epithelium. Nat Med 1: 1201-1203.
33. Boyle, MP, Enke, RA, Adams, RJ, Guggino, WB and Zeitlin, PL (2001). In utero AAV-mediated gene transfer to rabbit pulmonary epithelium. Mol Ther 4: 115-121.
34. Holzinger, A, Trapnell, BC, Weaver, TE, Whitsett, JA and Iwamoto, HS (1995). Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues. Pediatr Res 38: 844-850.
35. Larson, JE, Morrow, SL, Delcarpio, JB, Bohm, RP, Ratterree, MS, Blanchard, JL et al. (2000). Gene transfer into the fetal primate: evidence for the secretion of transgene product. Mol Ther 2: 631-639.
36. Bennett, M, Galan, H, Owens, G, Dewey, R, Banks, R, Hobbins, J et al. (2001). In utero gene delivery by intraamniotic injection of a retroviral vector producer cell line in a nonhuman primate model. Hum Gene Ther 12: 1857-1865.
37. Bilbao, R, Reay, DP, Li, J, Xiao, X and Clemens, PR (2005). Patterns of gene expression from in utero delivery of adenoviral-associated vector serotype 1. Hum Gene Ther 16: 678-684.
38. Boyle, MP, Enke, RA, Mogayzel, PJ Jr, Guggino, WB, Martin, DB, Agarwal, S et al. (2003). Effect of adeno-associated virus-specific immunoglobulin G in human amniotic fluid on gene transfer. Hum Gene Ther 14: 365-373.
39. Shelton, GD and Engvall, E (2005). Canine and feline models of human inherited muscle diseases. Neuromuscul Disord 15: 127-138.
40. Duan, D (2011). Duchenne muscular dystrophy gene therapy: Lost in translation? Res Rep Biol 2011: 31-42.
41. Shimatsu, Y, Katagiri, K, Furuta, T, Nakura, M, Tanioka, Y, Yuasa, K et al. (2003). Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 52: 93-97.
42. Miyazato, LG, Moraes, JR, Beretta, DC and Kornegay, JN (2011). Muscular dystrophy in dogs: does the crossing of breeds influence disease phenotype? Vet Pathol 48: 655-662.
43. Shin, JH, Pan, X, Hakim, CH, Yang, HT, Yue, Y, Zhang, K et al. (2013). Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther 21: 750-757.
44. Gayraud, J, Matecki, S, Hnia, K, Mornet, D, Prefaut, C, Mercier, J et al. (2007). Ventilation during air breathing and in response to hypercapnia in 5 and 16 monthold mdx and C57 mice. J Muscle Res Cell Motil 28: 29-37.
45. Ishizaki, M, Suga, T, Kimura, E, Shiota, T, Kawano, R, Uchida, Y et al. (2008). Mdx respiratory impairment following fibrosis of the diaphragm. Neuromuscul Disord 18: 342-348.
46. Takano, H, Fujii, Y, Yugeta, N, Takeda, S and Wakao, Y (2011). Assessment of left ventricular regional function in affected and carrier dogs with Duchenne muscular dystrophy using speckle tracking echocardiography. BMC Cardiovasc Disord 11: 23.
47. Moise, NS, Valentine, BA, Brown, CA, Erb, HN, Beck, KA, Cooper, BJ et al. (1991). Duchenne's cardiomyopathy in a canine model: electrocardiographic and echocardiographic studies. J Am Coll Cardiol 17: 812-820.
48. Herzog, RW, Fields, PA, Arruda, VR, Brubaker, JO, Armstrong, E, McClintock, D et al. (2002). Influence of vector dose on factor IX-specific T and B cell responses in muscledirected gene therapy. Hum Gene Ther 13: 1281-1291.
49. Unzu, C, Hervás-Stubbs, S, Sampedro, A, Mauleón, I, Mancheño, U, Alfaro, C et al. (2012). Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med 10: 122.
50. Matsushita, T, Elliger, S, Elliger, C, Podsakoff, G, Villarreal, L, Kurtzman, GJ et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5: 938-945.
51. Okada, T, Nonaka-Sarukawa, M, Uchibori, R, Kinoshita, K, Hayashita-Kinoh, H, Nitahara-Kasahara, Y et al. (2009). Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Hum Gene Ther 20: 1013-1021.
52. Briguet, A, Courdier-Fruh, I, Foster, M, Meier, T and Magyar, JP (2004). Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 14: 675-682.
53. Muller, J, Vayssiere, N, Royuela, M, Leger, ME, Muller, A, Bacou, F et al. (2001). Comparative evolution of muscular dystrophy in diaphragm, gastrocnemius and masseter muscles from old male mdx mice. J Muscle Res Cell Motil 22: 133-139.
54. Kobayashi, M, Nakamura, A, Hasegawa, D, Fujita, M, Orima, H and Takeda, S (2009). Evaluation of dystrophic dog pathology by fat-suppressed T2-weighted imaging. Muscle Nerve 40: 815-826.
55. Valentine, BA, Cooper, BJ, de Lahunta, A, O'Quinn, R and Blue, JT (1988). Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 88: 69-81.